ERBB2 and breast carcinoma: Given the significant difference in the allograft rejection score across breast cancer subtypes, we investigated the association of the score with patient survival in whole breast cancer as well as in an estrogen receptor (ER)-positive/human epidermal growth factor 2 (HER2)-negative, and in TNBC in both METABRIC and GSE96058 cohorts.